1. Parallel Integration between BioVentures
Daedeok BioCommunity
Parallel Integration between BioVentures

2. Korean BioVentures.. 10 years History Fast growing (~800 Start-ups)
Government’s support
World class in some bio-industry areas
Many ‘Platform Technology’ companies
Strong in Manpower
KOSDAQ

3. Why Bio Cluster? Bundling of Creating
technologies and product pipelines
Creating
stronger and more sustainable businesses

4. Daedeok BioCommunity(DBC) is
a Organic
“BioVenture Cluster”

5. Our Differences Incubation Center DBC Catalyzed by Public sector
Private companies
Main purpose
Tech. Incubation
Biz Alliance
Strategy
Technology transfer
Technology fusion
Joining
Unrestricted
Qualified members

6. Overview of DBC Located in Daedeok Valley, Melting Pot
Daedeok BioCommunity
Overview of DBC
Located in Daedeok Valley, Melting Pot
Strategic Cluster between BioVenture Companies
Comprised of 16 Fastest Growing BioVenture Companies
Has Competitive Infrastructure
Organized and Operated by INBIONET CORP.
inBioNET Corporation

7. Daedeok Valley.. Overview of DBC
Melting Pot of Technology & Techno-preneurs
                                                                                                                                     
27.8 km2 Area
116 Research Institutes
20,000 Researchers
70,000 Residents
800 Venture Companies
inBioNET Corporation

8. Our Advantages
Sharing of manpower, R&D infra & technologies can overcome limited resources of individuals
Cross-learning is effective when going global, financing, IPO, etc..
Government support can be done more efficiently
Networking with outside is much easier
Technology fusion makes members of the cluster more competitive

9. Variety of DBC Members Product-focused Service-focused
GENOTECH
INBIONET
IDR
IDGENE
GENOMICTREE
SMALLSOFT
COSBIOTECH
BIOPROGEN
LOKAS
HANCHEM
Product-focused
Service-focused
TOOLGEN
GENOFOCUS
CRYSTALGENOMICS
GENECHEM
Technology-oriented

10. Members of DBC INBIONET Corporation GenoTech Corporation ToolGen, Inc.
Microbial Engineering / Pharmaceuticals
GenoTech Corporation
Genomics, Genome Sequencing
ToolGen, Inc.
Zinc Finger Protein: Gene Switch
LOKAS Automation Corp.
Bioanalysis Instruments
Samchully Pharm., Co. Ltd.
Chemical & Biological Drug Synthesis
GenomicTree, Inc.
DNA Microarray Technology
IDGene, Co. Ltd.
Identification by DNA

11. Members of DBC GenoFocus Co. Ltd. BioProgen Co. Ltd. HanChem Co. Ltd.
Protein Evolution / Bacterial Surface Display
BioProgen Co. Ltd.
Protein Engineering
HanChem Co. Ltd.
Chemical Drug Synthesis
Bio/chemo informatics
IDR Co. Ltd.
SmallSoft Co. Ltd.
Bioinformatics on Genomics
Crystal Genomics Co. Ltd.
Drug Discovery Based on Structural Proteomics
Site-specific Gene Targeting Agents
GeneChem, Inc.
Functional Biomaterials
COS Biotech, Co Ltd.
inBioNET Corporation

12. Product Pipelines of DBC
Pharmaceuticals
Animal Nutrition / Animal Drugs
Probiotics / DFMs
BioAgricultural/BioEnvirionmental Products
Diagnostic PCR Kits
DNA Chips
Specific Products for Laboratory
Software for Genome Analysis
                                 
inBioNET Corporation

13. Service Pipelines of DBC
Whole Genome Sequencing
High-throughput Genomics
Bioinformatics Services
Protein Drug Delivery System Developmet
Custom DNA Chip Production Service
New Drug Development with Structural Biology & Computational Virtual Screening
Custom DNA/Peptide Synthesis
Cell Evolution with Engineered Zinc Finger Proteins
Evolution of Antigen, Antibody and Enzymes
inBioNET Corporation

14. Features of DBC Total Employees: 290 Total Researchers: 190 (73%)
Ph.D.: 57 Masters: 92
Total Investment: ~45 M USD
Total Revenue: ~30 M USD
Patent Applications Filed: 72
Scientific Articles Published: 117
Average Ages : 4.0 years
One IPO company
Researchers
inBioNET Corporation

15. Fermentation Plant Animal Drug Plant Chemical Plant Laboratories
Total Area: 110,000m2
Facility Area: 17,000m2

16. Support from Government
Establishing additional facilities;
Bioventure Town Plan
Coordinated by Daejeon City
50M $ / 5 years from Govn’t
Buildings and instruments

17. Cases of Alliance SARS DNA Chip development and commercialization
National research projects
In-community R&D projects
Microbial genome project
New drug screening
Evolution of industrial strains

18. Our Commitments Create Efficiency and Synergy
Stay Small, Strong, and Competitive
Cook a Bigger Pie for “All”
Develop “Package Technology”

19. INBIONET Corporation
Company Overview

20. Profile company overview
BioMedical Company
Spun-off from national research institute (KRIBB)
Focusing on commercial biotechnology (penetration to conventional market with biotech)
Generic Biologics will be our key business
Daedeok BioCommunity is growth engine for technology fusion & business alliance

21. Facts & Figures company overview
8 years old
Total Asset : 22 M USD
Employees : 83 (20, researchers)
Total Area : 110,000m2
Facilities : 20,000m2 (18 labs, 3 plants)
Total Revenue : 3.5 M USD (’02)
7 M USD (’03)

22. Business Sectors business
Pharmaceuticals
Biopharmaceuticals
Animal Drugs & Direct-fed Microbials
Medical Instruments & Diagnostics

23. Milestones company overview
Began the manufacture
of pharmaceuticals
Listed stocks on KOSDAQ
Moved Corp. HQ to
Daedock Science Town
Started distribution
of animal drugs
Established oversea basis
Started the manufacture
of microbial products
Started developing Biogenerics
Changed company name to inBioNET
Established
Built a fermentation plant

24. R&D technology
Accomplish 24 government-funded projects (40M $) for 7years
Technology transfer to USA company
Custom research for USA company
On-going projects:
Biopharmaceuticals development (5)
Govn’t-funded project (4)
Oversea (1)
Pharmaceuticals (2)

25. Entrepreneurship-based BioCluster to promote advanced bio-industry
is the key
to promote advanced bio-industry